Etomidate vs. Midazolam for Sedation During ERCP
Choledocholithiasis, Cholangiocarcinoma, Pancreatitis
About this trial
This is an interventional treatment trial for Choledocholithiasis focused on measuring Endoscopic Retrograde Cholangiopancreatography (ERCP), Conscious Sedation, etomidate, midazolam
Eligibility Criteria
Inclusion Criteria:
- All patients who are scheduled diagnositic or therapeutic ERCP.
- Age : more than 20 and less than 90 years old
- ASA(American Society of Anesthesiologists) classificiation : I, II, III
Exclusion Criteria:Patients following
- Refuse to be enrolled
- ASA American Society of Anesthesiologists)classification IV, V
- Breast feeder
- The mentally ill
- Drug abuser
- Hypersensitivity to sedative or opioids
- Alcohol intoxication or dependency
- Body mass index (BMI) 36kg/m2 or more
Unstable vital sign
- tachypnea, respiration rate more than 25/min or less than 10/min
- Oxygen saturation : 90% or less
- Systolic blood pressure : less than 90 mmHg or more than 180 mmHg
- Diastolic blood pressure : less than 50 mmHg or more than 100 mmHg
- Heart rate : more than 120 beat/min or less than 50 beat/min.
Sites / Locations
- 1Digestive Disease Center and Department of Internal Medicine, Cheju Halla General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Etomidate
Midazolam
This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.